Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jonathan Field

Internal Medicine New York, NY Medical Doctor

NPI 1578547006 CMS profile 297676

10 Union Sq E, New York, NY 10003

Open in the dashboard

General payments

$62,369

984 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$26,243 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Jonathan Field of New York, NY is reported in the CMS Open Payments database as having received $62,369 across 984 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $26,243 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $20,659 176
2024 General $3,638 138
2023 General $2,935 113
2022 General $6,757 225
2021 General $3,174 150
2020 General $1,439 86
2019 General $23,768 96

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jonathan Field
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Jonathan Field were reported at $20,659. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Jonathan Field Internal Medicine median Middle half National median
2019 $23,768 $159 $48–$570 $163
2020 $1,439 $119 $33–$402 $114
2021 $3,174 $135 $37–$521 $132
2022 $6,757 $141 $42–$496 $149
2023 $2,935 $149 $45–$519 $160
2024 $3,638 $154 $47–$537 $164
2025 $20,659 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Genentech USA, Inc. $22,434 45 payments
  2. Ionis Pharmaceuticals, Inc. $12,395 29 payments
  3. Genzyme Corporation $5,815 91 payments
  4. CSL Behring $5,794 75 payments
  5. GlaxoSmithKline, LLC. $3,890 273 payments
  6. AstraZeneca Pharmaceuticals LP $2,667 66 payments
  7. Novartis Pharmaceuticals Corporation $1,781 27 payments
  8. BioCryst US Sales Co., LLC $1,156 105 payments
  9. Pfizer Inc. $913 54 payments
  10. AbbVie, Inc. $703 21 payments
  11. Other $4,819 198 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $30,654 18 payments
  2. Food and Beverage $21,691 941 payments
  3. Travel and Lodging $5,432 15 payments
  4. Consulting Fee $4,205 5 payments
  5. Honoraria $200 2 payments
  6. Education $187 3 payments
Products named General payments · program years 2019–2025
  1. Xolair Immunology $22,434 45 payments
  2. DAWNZERA $12,346 25 payments
  3. DUPIXENT $7,362 135 payments
  4. Andembry $4,494 20 payments
  5. TRELEGY ELLIPTA $1,959 139 payments
  6. XOLAIR Respiratory $1,460 11 payments
  7. NUCALA $1,360 89 payments
  8. TEZSPIRE $1,310 19 payments
  9. Haegarda $1,188 49 payments
  10. Orladeyo $1,174 106 payments
  11. Other $9,994 432 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

328

Median for Allergy/ Immunology: 449

Drug cost

$173,169

Median for Allergy/ Immunology: $169,700

Branded share of claims

28.4%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Panzyga Immun Glob G(Igg)-Ifas/Glycine Brand 12 $95,544
Dupixent Syringe Dupilumab Brand 20 $73,150
Albuterol Sulfate Hfa Albuterol Sulfate Brand 33 $967
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 13 $910
Azelastine Hcl Generic 44 $808
Montelukast Sodium Generic 65 $599
Ipratropium Bromide Generic 28 $444
Levocetirizine Dihydrochloride Generic 16 $243
Fluticasone Propionate Generic 18 $171
Azithromycin Generic 20 $88

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 41 billing codes

Paid by Medicare

$44,085

Of which drugs: $5,915

Medicare patients

163

Average age 73

Services billed

2,638

99 women, 64 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 58%
Diabetes 34%
Ischemic heart disease 28%
COPD 18%
Depression 18%
Osteoporosis 17%
Cancer 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
$763 20 —
AUVI-Q
$341 — —
TRELEGY ELLIPTA
$283 — —
TEZSPIRE
$255 — —
Haegarda
$247 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

984 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record